Table 3.
Vaccine | Placebo | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shot | Antigen/Antibody | After Injection (Week) | Vaccine Type | Studies N | Efficacy | Lower Limit | Upper Limit | I-Squared | Studies N | Efficacy | Lower Limit | Upper Limit | I-Squared |
After 1st dose | RBD | 2 | Adenovirus-based | 4 | 0.603 | 0.471 | 0.722 | 73.8 | 2 | 0.004 | 0.001 | 0.027 | 0 |
Inactivated | 4 | 0.870 | 0.734 | 0.983 | 93.8 | 4 | 0.024 | 0.008 | 0.072 | 0 | |||
3 | Adenovirus-based | 2 | 0.976 | 0.939 | 0.997 | 0.0 | NA | NA | NA | NA | NA | ||
VLP | 8 | 0.238 | 0.091 | 0.375 | 84.3 | NA | NA | NA | NA | NA | |||
4 | Adenovirus-based | 2 | 0.966 | 0.942 | 0.980 | 0.0 | 2 | 0.004 | 0.001 | 0.027 | 0 | ||
Inactivated | 4 | 0.913 | 0.564 | 0.958 | 90.7 | 4 | 0.061 | 0.033 | 0.110 | 0 | |||
Pro-Subunit | 6 | 0.628 | 0.590 | 0.665 | 0.0 | NA | NA | NA | NA | NA | |||
S-protein | 2 | Inactivated | 2 | 0.293 | 0.182 | 0.437 | 0.0 | 2 | 0.083 | 0.032 | 0.202 | 0 | |
3 | Pro-Subunit | 4 | 0.790 | 0.474 | 0.874 | 91.0 | 4 | 0.021 | 0.005 | 0.079 | 0 | ||
4 | Inactivated | 2 | 0.396 | 0.269 | 0.539 | 0.0 | 2 | 0.021 | 0.003 | 0.134 | 0 | ||
Pro-Subunit | 4 | 0.873 | 0.671 | 0.892 | 91.9 | 4 | 0.021 | 0.005 | 0.079 | 0 | |||
NAb | 2 | Inactivated | 4 | 0.583 | 0.210 | 0.868 | 95.0 | 4 | 0.030 | 0.013 | 0.070 | 0 | |
3 | Pro-Subunit | 4 | 0.551 | 0.291 | 0.786 | 85.0 | 4 | 0.021 | 0.005 | 0.079 | 0 | ||
4 | Adenovirus-based | 2 | 0.547 | 0.496 | 0.596 | 76.8 | 2 | 0.008 | 0.002 | 0.031 | 0 | ||
Inactivated | 4 | 0.691 | 0.537 | 0.812 | 95.0 | 4 | 0.025 | 0.008 | 0.074 | 0 | |||
mRNA-based | 4 | 0.702 | 0.655 | 0.746 | 73.9 | 4 | 0.010 | 0.004 | 0.026 | 0 | |||
After 2nd dose | RBD | 2 | Inactivated | 9 | 0.929 | 0.876 | 0.960 | 61.8 | 9 | 0.171 | 0.077 | 0.336 | 85 |
mRNA-based | 5 | 0.731 | 0.532 | 0.866 | 86.0 | NA | NA | NA | NA | NA | |||
3 | Adenovirus-based | 3 | 0.982 | 0.980 | 0.984 | 0.0 | 1 | 0.149 | 0.139 | 0.159 | 0 | ||
VLP | 9 | 0.787 | 0.581 | 0.908 | 78.1 | NA | NA | NA | NA | NA | |||
4 | Inactivated | 4 | 0.944 | 0.842 | 0.982 | 15.9 | 4 | 0.063 | 0.026 | 0.143 | 0 | ||
Pro-Subunit | 6 | 0.956 | 0.937 | 0.970 | 0.0 | NA | NA | NA | NA | NA | |||
S-protein | 2 | Inactivated | 7 | 0.941 | 0.877 | 0.973 | 61.4 | 7 | 0.290 | 0.139 | 0.507 | 87 | |
Pro-Subunit | 18 | 0.852 | 0.719 | 0.928 | 62.4 | 18 | 0.028 | 0.014 | 0.052 | 0 | |||
mRNA-based | 5 | 0.786 | 0.725 | 0.836 | 0.0 | NA | NA | NA | NA | NA | |||
4 | Inactivated | 4 | 0.934 | 0.842 | 0.974 | 15.9 | 4 | 0.063 | 0.026 | 0.143 | 0 | ||
Pro-Subunit | 14 | 0.792 | 0.679 | 0.873 | 50.7 | 15 | 0.031 | 0.015 | 0.061 | 0 | |||
NAbs | 2 | Adenovirus-based | 1 | 0.999 | 0.985 | 1.000 | 0.0 | NA | NA | NA | NA | NA | |
Inactivated | 9 | 0.845 | 0.724 | 0.919 | 86.5 | 9 | 0.151 | 0.068 | 0.303 | 85 | |||
Pro-Subunit | 23 | 0.753 | 0.667 | 0.823 | 68.2 | 19 | 0.028 | 0.015 | 0.052 | 0 | |||
mRNA-based | 9 | 0.870 | 0.747 | 0.938 | 82.4 | 4 | 0.008 | 0.003 | 0.024 | 0 | |||
3 | Adenovirus-based | 1 | 0.958 | 0.955 | 0.961 | 0.0 | 1 | 0.071 | 0.065 | 0.079 | 0 | ||
4 | Adenovirus-based | 1 | 0.999 | 0.985 | 1.000 | 0.0 | NA | NA | NA | NA | NA | ||
Inactivated | 4 | 0.700 | 0.375 | 0.901 | 86.1 | 4 | 0.033 | 0.011 | 0.099 | 0 | |||
Pro-Subunit | 17 | 0.759 | 0.574 | 0.881 | 62.9 | 15 | 0.031 | 0.015 | 0.061 | 0 | |||
mRNA-based | 4 | 0.995 | 0.980 | 0.999 | 0.0 | 4 | 0.016 | 0.007 | 0.035 | 0 |
S-protein = spike protein, Alum = aluminium, CpG = cytosine-guanine oligodeoxynucleotide, AS03 = squalene-based immunologic adjuvant, RBD = receptor-binding domain, NAb = neutralizing antibody, Pro-Subunit = protein subunit, NA = not available.